Budenaz 0.5 Respules (2ml Each) - for nebulization- 5 pcs

Budenaz 0.5 Respules are a pharmaceutical suspension intended for nebulization, containing the active ingredient Budesonide. Each respule contains 0.

5 mg of Budesonide in a 2 ml volume. This formulation is designed for direct delivery to the respiratory tract via a nebulizer device. Budesonide is a synthetic corticosteroid with potent anti-inflammatory properties.

Its mechanism of action involves reducing inflammation within the airways by inhibiting the release of inflammatory mediators. This action helps to decrease swelling, mucus production, and bronchoconstriction, thereby improving airflow and alleviating respiratory symptoms.

The primary application of Budenaz 0.5 Respules is in the management of inflammatory respiratory conditions. This includes the long-term control and prevention of asthma symptoms in both pediatric and adult patients.

It is also utilized in the treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, where airway inflammation contributes significantly to the disease process. Furthermore, it may be prescribed for other conditions characterized by airway inflammation that are amenable to inhaled corticosteroid therapy.

This product is intended for use by medical professionals, patients under their care, and caregivers administering treatment. The respules are designed for single-use nebulization. The liquid suspension is poured into the nebulizer chamber, and the patient inhales the aerosolized medication.

The delivery of Budesonide directly to the lungs ensures a targeted therapeutic effect, minimizing systemic absorption and potential side effects associated with oral corticosteroids. The precise dosage and frequency of administration are determined by a qualified healthcare provider based on the patient's age, condition severity, and response to treatment.

Key benefits of using Budenaz 0.5 Respules include the reduction of airway inflammation, which can lead to a decrease in the frequency and severity of asthma exacerbations and COPD flare-ups. Patients may experience improved breathing comfort, reduced coughing, and diminished wheezing.

The targeted delivery system promotes effective symptom control and can contribute to improved lung function over time. It is important to note that this medication is for maintenance therapy and not for immediate relief of acute bronchospasm or asthma attacks.

Usage requires strict adherence to medical guidance. After each nebulization session, patients are advised to rinse their mouth with water. This practice helps to reduce the risk of localized side effects such as oral candidiasis (thrush).

The respules should be stored according to manufacturer instructions, typically protected from light and kept out of reach of children. Any pre-existing medical conditions, particularly active infections such as tuberculosis, viral, or fungal infections, should be disclosed to the prescribing physician prior to initiating treatment with Budenaz 0.5 Respules.

The product is for inhalation use only and should never be ingested or administered by injection.

These respules are manufactured from medical-grade materials to ensure product integrity and patient safety. Each pack contains 5 individual 2 ml respules. The formulation is a liquid suspension, ready for direct use in compatible nebulizer devices.

The packaging is designed to maintain sterility until the point of use. Proper handling and disposal of used respules are also important considerations for infection control and environmental safety.